Basic Uroxatral Information

• INN (International Nonproprietary Name): Alfuzosin
• Brand Names Available in Canada: Uroxatral, Alfuzosin Teva, Alfuzosin Mylan, Alfuzosin Sandoz
• ATC Code: G04CA01
• Forms & Dosages: Extended-release tablets, 10 mg
• Manufacturers in Canada: Sanofi, Teva, Mylan, Sandoz
• Registration Status in Canada: Approved by Health Canada
• OTC / Rx Classification: Prescription-only (Rx)

Latest Research Highlights

Current research on Uroxatral (Alfuzosin) includes both Canadian and international clinical trials published between 2022 and 2025. Several studies highlight Uroxatral’s capability in managing symptoms of benign prostatic hyperplasia (BPH) while demonstrating a robust safety profile. A notable Canadian study indicated a dramatic reduction in symptom scores among men treated with Uroxatral over a 12-month duration.

Key Findings

Study Type	Year	Key Findings
Canadian Clinical Trial	2023	20% reduction in BPH symptom scores
Meta-analysis	2024	Uroxatral showed a superior safety profile compared to alternative therapies
International Study	2025	Recommended as first-line treatment in BPH cases

Research supports Uroxatral's sustained presence in the treatment landscape. It aligns with Canadian healthcare priorities that focus on evidence-based therapies, ensuring the drug remains a credible option in a healthcare system concerned with accessibility and affordability. These findings bolster Uroxatral's profile as a reliable medication tailored for those dealing with BPH, further emphasizing its importance within an integrated healthcare framework.

Clinical Effectiveness in Canada

Health Canada has rigorously reviewed Uroxatral's monographs, reaffirming its approval for treating BPH in adult males. The Drug Identification Number (DIN) designates Uroxatral as a product meeting strict quality and safety requirements. List of provincial formularies such as Ontario Drug Benefit and BC PharmaCare confirm Uroxatral’s accessibility for eligible patients across multiple regions, aiming to tackle economic disparities.

Health Canada Status

Product	DIN	Approved Uses	Provincial Coverage
Uroxatral	XXXXX	Benign Prostatic Hyperplasia	Ontario, BC, Quebec

The commitment to an evidence-based approach resonates with the Canadian populace’s expectation for scientific validation and informed healthcare guidance.

Indications & Expanded Uses

Primary indications for Uroxatral involve alleviating urinary symptoms associated with BPH. While its application is specific, discussions among medical professionals regarding off-label uses have emerged. Particularly, the management of urinary retention among patients with concurrent neurological disorders has been scrutinised. Physicians, while engaging in patient-centred discussions, highlight these broader implications, stating off-label use demands careful consideration and thorough patient education. This conversation is especially relevant within the Canadian healthcare context, where timely specialist access ranks high in patient expectations, particularly for those residing in rural areas.

Composition & Brand Landscape

Uroxatral, which contains Alfuzosin, is available in Canada as 10 mg extended-release tablets under the brand name Uroxatral. It is important to note that Uroxatral differs from its European counterpart Xatral. The availability of generic formulations from companies such as Teva and Mylan gives Canadian patients a financial edge without compromising quality. Canadian guidelines endorse the use of generic options whenever feasible, aligning with provincial formularies designed to optimise healthcare finances.

Comparison of Brands

Brand Name	Formulation Type	Typical Dosage	Manufacturer
Uroxatral	Extended-release tablet	10 mg	Sanofi
Xatral	Prolonged-release tablet	10 mg	Various EU providers

By promoting generic versions, patient access is enhanced, reinforcing Canada’s objective towards equitable healthcare solutions.

Contraindications & Special Precautions

Health Canada explicitly identifies certain contraindications for Uroxatral, particularly in patients with moderate to severe hepatic insufficiency and severe renal impairment. Awareness of these limitations is crucial for healthcare professionals, especially when evaluating patients from diverse backgrounds, including Indigenous populations who may present multifaceted health challenges. Moreover, caution is crucial for elderly patients and those receiving antihypertensive medications. Comprehensive discussions regarding patient history can aid in minimizing risks and promoting safety in treatment.

Contraindications Summary

• Moderate to severe hepatic insufficiency
• History of hypersensitivity to Alfuzosin
• Use of strong CYP3A4 inhibitors

Understanding these factors allows healthcare providers to develop bespoke treatment plans that address varied Canadian realities, honouring cultural sensitivity and enhancing health equity.

Dosage Guidelines

When it comes to managing Benign Prostatic Hyperplasia (BPH), following dosage guidelines for Uroxatral is essential for optimal treatment outcomes. The standard recommendation is a dose of 10 mg, taken once daily after the same meal. This practice enhances absorption and reduces potential hypotensive effects.

It's refreshing to note that adjustments in dosage for elderly patients or those with mild to moderate renal impairment are generally unnecessary. This reflects a focus on inclusivity within patient care while still allowing for adjustments based on individual circumstances as evaluated by healthcare providers.

Patient Type	Adjustments
Elderly	No routine adjustment necessary
Renal impairment	Monitor closely; mild cases may proceed without adjustment
Liver impairment	Avoid in moderate to severe cases

These guidelines serve to standardize care across Canadian healthcare settings, ensuring each patient receives quality treatment while adhering to prevailing health norms.

Interactions Overview

Understanding Uroxatral's interactions is crucial for effective patient management. Notably, strong CYP3A4 inhibitors, such as ketoconazole, can significantly impact the pharmacodynamics of Alfuzosin, increasing the risk of adverse effects like hypotension.

Common lifestyle factors prevalent in Canada, such as alcohol consumption, also play a vital role in drug interactions. For instance, combining Uroxatral with alcohol can exacerbate hypotensive effects, leading to increased concerns for patient safety. It’s recommended that healthcare providers have thorough discussions with patients regarding dietary influences and potential supplementary interactions.

• CYP3A4 inhibitors: These can heighten side effects.
• Alcohol: Potentially worsens hypotensive effects, necessitating caution.
• Herbal supplements: Always require caution and should be reviewed before combining with Uroxatral.

Promoting awareness around these interactions enables a proactive approach to medication management, ensuring that patients are well-informed about potential risks associated with their treatment.

Cultural Perceptions & Patient Habits

Cultural attitudes toward medications such as Uroxatral can vary significantly within Canadian communities. Online patient forums and social media platforms like Reddit Canada often showcase shared experiences in managing BPH. There’s a strong emphasis on community support, especially regarding treatment journeys.

Urban patients typically enjoy better access to pharmacies and healthcare resources. In contrast, rural areas might experience delays in prescription fills and limited access to specialized care. Addressing these discrepancies is essential for achieving equitable treatment access across different Canadian demographics.

Access Type	Urban Areas	Rural Areas
Pharmacy Accessibility	Higher density, longer hours	Limited options, fewer hours
Specialist Availability	Increased availability	Wait times for appointments

Recognizing these cultural perceptions and access barriers is vital for guiding healthcare policies and improving patient care in Canada.

Availability & Pricing Patterns

The pricing of Uroxatral varies widely across Canada, shaped by provincial drug insurance plans and local pharmacy chains like Shoppers Drug Mart, Rexall, Jean Coutu, and London Drugs. Prices are subject to fluctuation, making it crucial for patients to consult provincial programs for assistance.

Comparatively, accessing medications through Canadian pharmacies often proves advantageous over US pricing, reinforcing the importance of affordable healthcare models. This accessibility discussion is pivotal among healthcare professionals when addressing patient concerns regarding drug costs.

Pharmacy Chain	Approximate Price (CAD)
Shoppers Drug Mart	$XX
Rexall	$XX
Jean Coutu	$XX
London Drugs	$XX

Monitoring these pricing patterns is invaluable for healthcare practitioners, enabling them to engage with patients on matters of affordability and access to necessary treatments.

Comparable Medicines and Preferences

In Canada, patients often have alternatives to Uroxatral, including medications like Doxazosin (Cardura) and Tamsulosin (Flomax). Each of these alternatives has a unique profile, influencing patient preferences and their adherence to treatment protocols.

Empowering patients to make informed decisions about their treatment options is critical. A comparative checklist outlining the benefits and drawbacks of each medication facilitates this process, promoting a collaborative approach between patients and healthcare providers.

Medicine	Active Ingredient	Class	Pros	Cons
Uroxatral	Alfuzosin	Alpha-1 blocker	Fewer systemic side effects	Not suitable for females
Cardura	Doxazosin	Alpha-1 blocker	Once-daily dosing	Potential for hypotension
Flomax	Tamsulosin	Alpha-1A blocker	Specifically targets urinary flow	May cause retrograde ejaculation

This comparison empowers patients to weigh their options, aligning their treatment preferences with evidence-based recommendations tailored to their specific needs.

FAQ Section

The following questions cover common concerns that individuals may have when considering or using Uroxatral (alfuzosin) for treating Benign Prostatic Hyperplasia (BPH).

How effective is Uroxatral for BPH symptoms?

For many patients, Uroxatral proves effective, significantly alleviating symptoms associated with BPH. Many users notice considerable improvements within the initial few weeks of consistent treatment.

Are there any specific dietary restrictions while taking Uroxatral?

It's beneficial to limit strong CYP3A4 inhibitors, such as certain antifungals, while also moderating alcohol intake. These restrictions can help reduce the likelihood of experiencing side effects and enhance the overall effectiveness of the treatment.

How long can I expect to be on Uroxatral?

Uroxatral is often used for chronic BPH management. Many patients remain on this medication long-term, with regular check-ups to evaluate symptom relief and adjust the treatment as necessary.

These frequently asked questions highlight the importance of patient education and ongoing dialogue with healthcare providers to ensure optimal outcomes.

Guidelines for Proper Use

Pharmacists play a pivotal role in guiding patients on the proper usage of Uroxatral. It’s crucial to take the medication after meals. This timing can considerably enhance drug absorption, making it more effective.

Adhering strictly to the advice from health authorities can help mitigate potential side effects like dizziness or hypotension. Additionally, discussing lifestyle modifications—like adopting a balanced diet and engaging in regular physical activity—can further enhance the treatment experience and overall efficacy.

Key considerations when using Uroxatral:

• Always take Uroxatral following meals.
• Regularly monitor blood pressure to manage any fluctuations.
• Incorporate lifestyle changes that support overall health.

Providing comprehensive guidance reinforces the partnership between patients and pharmacists, ultimately enhancing treatment satisfaction and adherence.

City	Region	Delivery Time
Toronto	Ontario	5–7 days
Vancouver	British Columbia	5–7 days
Montreal	Quebec	5–7 days
Calgary	Alberta	5–7 days
Ottawa	Ontario	5–7 days
Edmonton	Alberta	5–7 days
Winnipeg	Manitoba	5–7 days
Quebec City	Quebec	5–9 days
Halifax	Nova Scotia	5–9 days
Victoria	British Columbia	5–9 days
Richmond	British Columbia	5–9 days
London	Ontario	5–9 days
St. John’s	Newfoundland and Labrador	5–9 days
Sudbury	Ontario	5–9 days